AnaptysBio (ANAB) vs GH Research (GHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Over five years, ANAB leads with a +138.8% price change compared with +23.9% for GHRS. GH Research is the larger company by market cap ($1.45 billion vs $1.36 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | GHRS |
|---|---|---|
| Share price | $45.65 | $21.06 |
| Market cap | $1.36B | $1.45B |
| 1-day change | -4.68% | -2.14% |
| YTD return | — | +65.83% |
| 1-year return | — | +60.89% |
| 5-year return | +138.84% | +23.88% |
| Forward P/E | 9.01 | — |
| EPS (TTM) | $-0.96 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $31.44 |
| 52-week low | $20.18 | $12.04 |
| Distance from 52-week high | -36.91% | -33.01% |
| Average volume | 569.55K | 295.05K |
| Shares outstanding | 29.90M | 68.64M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ANAB vs GHRS FAQ
Which is bigger, AnaptysBio or GH Research?
GH Research (GHRS) is larger, with a market capitalization of $1.45B compared with $1.36B for AnaptysBio (ANAB).
Are AnaptysBio and GH Research in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.